Hepatic stellate cell activation state (HSC activation)

Hepatic stellate cells (HSCs) are the central mediators of liver fibrosis, residing in the perisinusoidal space of Disse. In a healthy physiological state, these cells are quiescent and function primarily to store vitamin A in lipid droplets (Friedman, 2008, PubMed). However, in response to chronic liver injury—such as viral hepatitis, alcohol abuse, or fatty liver disease—HSCs undergo a complex activation process known as transdifferentiation. This transition converts them into proliferative, contractile, and pro-inflammatory myofibroblasts that secrete excessive amounts of extracellular matrix (ECM) proteins, leading to fibrosis and eventually cirrhosis (Tsuchida & Friedman, 2017, Nat Rev Gastroenterol Hepatol). The activation state is regulated by a network of signaling pathways, including TGF-beta, PDGF, and various inflammatory cytokines. Therapeutic strategies targeting the HSC activation state focus on inhibiting these profibrotic signals, inducing apoptosis in activated cells, or promoting their reversion to a quiescent phenotype. Drugs such as FXR agonists (e.g., obeticholic acid) and PPAR-gamma agonists (e.g., pioglitazone) are being investigated for their ability to modulate this cellular state in diseases like non-alcoholic steatohepatitis (NASH) (NIH/NIDDK). Because "Hepatic stellate cell activation state" describes a cellular phenotype rather than a single protein, it is considered a biological process target rather than a discrete molecular receptor.

Other names

HSC activationHepatic stellate cell transdifferentiationMyofibroblastic transformation of HSCsHSC myofibroblast activation

Modulation of the hepatic stellate cell activation state involves the inhibition of profibrotic signaling pathways (e.g., TGF-β/Smad, PDGF), the activation of nuclear receptors that maintain cellular quiescence (e.g., FXR, PPAR-γ), or the induction of activated cell apoptosis and extracellular matrix degradation.